BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Feb 14, 2020
Finance

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

Within one month of its stock reaching an all-time high, Innovent priced its second follow-on offering on the Hong Kong exchange early Thursday, raising HK$2.4 billion ($303.2 million) to expand manufacturing capacity in preparation for...
BioCentury | Jan 17, 2020
Translation in Brief

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas. The premise of synthetic lethality is...
BioCentury | Oct 20, 2016
Translation in Brief

Viking’s heart bypass

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214 , cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy (X-ALD)....
BioCentury | May 12, 2016
Emerging Company Profile

Crowdsourcing cells

Most suppliers of research-grade induced pluripotent stem (iPS) cells provide samples from a small number of individuals, limiting the customer's ability to study a diverse patient population, and charge prices that make routine use of...
BioCentury | Apr 27, 2015
Company News

GenVec Inc, TheraBiologics deal

GenVec and TheraBiologics partnered to develop cancer therapeutics using GenVec’s gene delivery technology and TheraBiologics’ neural stem cell (NSC) technology. GenVec will contribute vector construction, and TheraBiologics will be responsible for development costs. The first...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Notum pectinacetylesterase homolog (NOTUM); wingless-type MMTV integration site (WNT) Patent and licensing status unavailable

Cancer INDICATION: Cancer In vitro and in vivo studies suggest NOTUM could help treat WNT-driven cancers. In fruit flies, overexpression of fly NOTUM suppressed the expression of a gene activated by high levels of WNT...
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Carboxylesterase 1 (CES1; hCE1) In vitro and mouse studies suggest inhibiting CES1 could help treat type 2 diabetes. In...
BioCentury | May 7, 2012
Clinical News

Tysabri natalizumab: Interim postmarketing study data

Interim data from the international TYNERGY trial in 195 patients showed that Tysabri significantly reduced median FSMC scores by 9 points from baseline to 12 months (p<0.0001). Tysabri also led to significant reductions in the...
BioCentury | Sep 6, 2010
Company News

Lab21, Medical University of South Carolina deal

The university granted Lab21 an exclusive, worldwide license to IP covering the detection and analysis of genetic variants of the human carboxylesterase 1 ( CES1 ; hCE1 ) gene. Lab21 plans to offer CES1 analysis through its...
Items per page:
1 - 10 of 11